GSK has been the topic of several other reports. BNP Paribas reaffirmed an underperform rating and set a GBX 1,520 ($19.62) target price on shares of GlaxoSmithKline plc in a report on Sunday, January 15th. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a report on Friday, January 6th. Jefferies Group LLC raised their target price on GlaxoSmithKline plc from GBX 1,780 ($22.98) to GBX 1,800 ($23.23) and gave the stock a buy rating in a report on Friday, February 17th. Beaufort Securities reaffirmed a buy rating and set a GBX 1,750 ($22.59) target price on shares of GlaxoSmithKline plc in a report on Thursday, February 16th. Finally, Goldman Sachs Group Inc raised their target price on GlaxoSmithKline plc from GBX 1,800 ($23.23) to GBX 1,850 ($23.88) and gave the stock a buy rating in a report on Tuesday, January 24th. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. GlaxoSmithKline plc has a consensus rating of Hold and a consensus target price of GBX 1,743.36 ($22.50).
The business also recently announced a dividend, which will be paid on Thursday, July 13th. Investors of record on Thursday, May 11th will be paid a dividend of GBX 19 ($0.25) per share. The ex-dividend date of this dividend is Thursday, May 11th. This represents a yield of 1.21%.
In related news, insider Moncef Slaoui bought 56 shares of the stock in a transaction that occurred on Tuesday, March 7th. The stock was purchased at an average cost of GBX 2,072 ($26.75) per share, with a total value of £1,160.32 ($1,497.77). Also, insider Vivienne Cox bought 335 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were bought at an average cost of GBX 1,583 ($20.43) per share, with a total value of £5,303.05 ($6,845.29). Insiders have purchased a total of 718 shares of company stock valued at $1,183,024 over the last three months.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.